Search

Displaying results 6191 - 6200 of 10000 in total
  1. Drug

    Pentafluoropropane

    go.drugbank.com/drugs/DB13117
    ApprovedWithdrawn

    Pentafluoropropane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).

  2. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.

  3. Drug

    Ralmitaront

    go.drugbank.com/drugs/DB19128
    Investigational

    Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or

    Synonyms: 1h-pyrazole-3-carboxamide, 5-ethyl-4-methyl-n-(4-(2s)-2-morpholinylphenyl)-, 5-ethyl-4-methyl-n-(4-((2s)-morpholin-2-yl)phenyl)-1h-pyrazole-3-carboxamide
  4. Drug

    Refametinib

    go.drugbank.com/drugs/DB06309
    Investigational

  5. Drug

    NAV 1800

    go.drugbank.com/drugs/DB05437
    Experimental

    RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal

  6. Drug

    Vercirnon

    go.drugbank.com/drugs/DB15250
    Investigational

    Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. … It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).

    International brands: Traficet-EN
  7. Drug

    BO-653

    go.drugbank.com/drugs/DB19216
    Investigational

    BO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and … Effectiveness in Preventing Post-angioplasty Blood Vessel Re-closure (Restenosis) in Stented Vessels.).

  8. Drug

    N4-Hydroxycytidine

    go.drugbank.com/drugs/DB15660
    Experimental

    [A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. … N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.

    Synonyms: 4-N-Hydroxycytidine, N(4)-Hydroxycytidine
  9. Drug

    AVI-4020

    go.drugbank.com/drugs/DB05873
    Investigational

    AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).

  10. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.